172 related articles for article (PubMed ID: 18562414)
1. Neuroendocrine and subjective responses to pharmacological challenge with citalopram: a controlled study in male and female ecstasy/MDMA users.
Allott K; Canny BK; Broadbear JH; Stepto NK; Murphy B; Redman J
J Psychopharmacol; 2009 Sep; 23(7):759-74. PubMed ID: 18562414
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: is it ecstasy or cannabis?
Gouzoulis-Mayfrank E; Becker S; Pelz S; Tuchtenhagen F; Daumann J
Biol Psychiatry; 2002 May; 51(9):766-9. PubMed ID: 11983191
[TBL] [Abstract][Full Text] [Related]
3. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
4. Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users.
Wetherell MA; Montgomery C
Psychopharmacology (Berl); 2014 Apr; 231(7):1365-75. PubMed ID: 24190587
[TBL] [Abstract][Full Text] [Related]
5. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users.
McCann UD; Eligulashvili V; Mertl M; Murphy DL; Ricaurte GA
Psychopharmacology (Berl); 1999 Nov; 147(1):56-65. PubMed ID: 10591869
[TBL] [Abstract][Full Text] [Related]
6. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers.
Liechti ME; Vollenweider FX
J Psychopharmacol; 2000; 14(3):269-74. PubMed ID: 11106307
[TBL] [Abstract][Full Text] [Related]
7. Serotonergic function after (+/-)3,4-methylene-dioxymethamphetamine ('Ecstasy') in humans.
Gerra G; Zaimovic A; Giucastro G; Maestri D; Monica C; Sartori R; Caccavari R; Delsignore R
Int Clin Psychopharmacol; 1998 Jan; 13(1):1-9. PubMed ID: 9988361
[TBL] [Abstract][Full Text] [Related]
8. Mapping serotonergic dysfunction in MDMA (ecstasy) users using pharmacological MRI.
Schouw ML; Gevers S; Caan MW; Majoie CB; Booij J; Nederveen AJ; Reneman L
Eur Neuropsychopharmacol; 2012 Aug; 22(8):537-45. PubMed ID: 22209360
[TBL] [Abstract][Full Text] [Related]
9. Is recreational ecstasy (MDMA) use associated with higher levels of depressive symptoms?
Guillot C
J Psychoactive Drugs; 2007 Mar; 39(1):31-9. PubMed ID: 17523583
[TBL] [Abstract][Full Text] [Related]
10. Attributions for psychobiological changes in ecstasy/MDMA and other polydrug users.
Soar K; Parrott A; Turner J
J Psychopharmacol; 2009 Sep; 23(7):745-58. PubMed ID: 18635698
[TBL] [Abstract][Full Text] [Related]
11. Event related potential (ERP) evidence for selective impairment of verbal recollection in abstinent recreational methylenedioxymethamphetamine ("Ecstasy")/polydrug users.
Burgess AP; Venables L; Jones H; Edwards R; Parrott AC
Psychopharmacology (Berl); 2011 Aug; 216(4):545-56. PubMed ID: 21390504
[TBL] [Abstract][Full Text] [Related]
12. Memory deficits associated with recreational use of "ecstasy" (MDMA).
Morgan MJ
Psychopharmacology (Berl); 1999 Jan; 141(1):30-6. PubMed ID: 9952062
[TBL] [Abstract][Full Text] [Related]
13. Differences in prefrontal blood oxygenation during an acute multitasking stressor in ecstasy polydrug users.
Roberts CA; Wetherell MA; Fisk JE; Montgomery C
Psychol Med; 2015 Jan; 45(2):395-406. PubMed ID: 25066866
[TBL] [Abstract][Full Text] [Related]
14. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
[TBL] [Abstract][Full Text] [Related]
15. Impulsivity, risk taking and recreational 'ecstasy' (MDMA) use.
Butler GK; Montgomery AM
Drug Alcohol Depend; 2004 Oct; 76(1):55-62. PubMed ID: 15380289
[TBL] [Abstract][Full Text] [Related]
16. Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: reduced depression 1 year after giving birth and quitting Ecstasy.
Turner JJ; Parrott AC; Goodwin J; Moore DG; Fulton S; Min MO; Singer LT
J Psychopharmacol; 2014 Jan; 28(1):55-61. PubMed ID: 24327452
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
Gouzoulis-Mayfrank E; Daumann J
Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
[TBL] [Abstract][Full Text] [Related]
18. Ecstasy (MDMA) does not have long-term effects on aggressive interpretative bias: a study comparing current and ex-ecstasy users with polydrug and drug-naive controls.
Hoshi R; Cohen L; Lemanski L; Piccini P; Bond A; Curran HV
Exp Clin Psychopharmacol; 2007 Aug; 15(4):351-8. PubMed ID: 17696682
[TBL] [Abstract][Full Text] [Related]
19. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram.
Liechti ME; Baumann C; Gamma A; Vollenweider FX
Neuropsychopharmacology; 2000 May; 22(5):513-21. PubMed ID: 10731626
[TBL] [Abstract][Full Text] [Related]
20. Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation.
Daumann J; Hensen G; Thimm B; Rezk M; Till B; Gouzoulis-Mayfrank E
Psychopharmacology (Berl); 2004 May; 173(3-4):398-404. PubMed ID: 14722704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
